# Phase 2/3 Study to Evaluate PK, Safety & Efficacy of INM004 in STEC Positive Pediatric Patients for Prevention of HUS

> **NCT04132375** · PHASE2,PHASE3 · TERMINATED · sponsor: **Inmunova S.A.** · enrollment: 11 (actual)

## Conditions studied

- Bloody Diarrhea
- STEC, Unspecified
- Hemolytic-Uremic Syndrome
- Pediatric Kidney Disease

## Interventions

- **DRUG:** INM004
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04132375
- **Lead sponsor:** Inmunova S.A.
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-07-17
- **Primary completion:** 2022-05-04
- **Final completion:** 2022-07-19
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Due to COVID pandemia enrolment was stopped on 20March2020
- **Last updated:** 2023-07-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04132375

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04132375, "Phase 2/3 Study to Evaluate PK, Safety & Efficacy of INM004 in STEC Positive Pediatric Patients for Prevention of HUS". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04132375. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*